Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Hoth Therapeutics, Inc. (HOTH : NSDQ)

• Company Description    Hoth Therapeutics Inc. is a development stage biopharmaceutical company. It focused on therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema. The company's BioLexa(TM) Platform is a proprietary, patented drug compound platform. Hoth Therapeutics Inc. is based in New York, United States. Number of Employees: 3

• Price / Volume Information    Yesterday's Closing Price: $1.17 Daily Weekly Monthly 20 Day Moving Average: 215,602 shares Shares Outstanding: 15.51 (millions) Market Capitalization: $18.15 (millions) Beta: 0.64 52 Week High: $3.80 52 Week Low: $0.66 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -0.85% -2.15% 12 Week -39.06% -40.81% Year To Date 56.40% 37.85%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1177 Avenue of the Americas 5th Floor Suite 5066 - New York,NY 10036 USA ph: 646-756-2997 fax: - investorrelations@hoththerapeutics.com https://hoththerapeutics.com

• General Corporate Information    Officers Robb Knie - President; Chief Executive Officer and Director David Briones - Chief Financial Officer Wayne Linsley - Director David B. Sarnoff - Director Graig Springer - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 44148G204 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/27/26 Share - Related Items Shares Outstanding: 15.51 Most Recent Split Date: 10.00 (0.04:1) Beta: 0.64 Market Capitalization: $18.15 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/27/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.88 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 3.23% vs. Previous Quarter: -76.47% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - -133.69 06/30/25 - -114.32 03/31/25 - -109.18 ROA 09/30/25 - -123.43 06/30/25 - -105.92 03/31/25 - -100.22 Current Ratio 09/30/25 - 8.81 06/30/25 - 27.54 03/31/25 - 15.09 Quick Ratio 09/30/25 - 8.81 06/30/25 - 27.54 03/31/25 - 15.08 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - 0.62 06/30/25 - 0.74 03/31/25 - 0.88 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©